Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

NCT ID: NCT00864604

Last Updated: 2020-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-30
• Study Completion Date: 2007-05-31

Brief Summary

The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence

Detailed Description

Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.

Official Title: Single Dose Two-Way Crossover Fed Bioequivalence Study of

Nabumetone 750 mg Tablets in Healthy Volunteers Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

A

Nabumetone 750 mg tablets, single dose

Group Type: EXPERIMENTAL

Nabumetone 750 mg tablets, single dose

Intervention Type: DRUG

A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions

B

Nabumetone 750 mg tablets, single dose

Group Type: ACTIVE_COMPARATOR

Nabumetone 750 mg tablets, single dose

Intervention Type: DRUG

B: Active comparator Subjects received Teva formulated products under fed conditions

Interventions

Nabumetone 750 mg tablets, single dose

A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions

Intervention Type: DRUG

Nabumetone 750 mg tablets, single dose

B: Active comparator Subjects received Teva formulated products under fed conditions

Intervention Type: DRUG

Other Intervention Names

Nabumetone; Nabumetone

Eligibility Criteria

Inclusion Criteria

1. Healthy subjects at least 18 years of age.

2. Availability of the subject for the entire study period and willingness to provide written informed consent after being informed of the nature of the study.

3. Body mass index (BMI) between 18 and 30 kg/m2 (calculated using the BMI Calculator on the Centers for Disease Control and Prevention [CDC] website available at http://www.cdc.gov/nccdphp/dnpa/bmi/index.htm, last accessed 19 Mar 07) and a weight of at least 110 pounds.

4. Good health as determined by a lack of clinically significant abnormalities in health assessments performed at Screening, as judged by the physician.

5. Females were required to use a medically acceptable method of hormonal contraception or abstinence throughout the entire study period and for one week after the study is completed

Exclusion Criteria

1. Hypersensitivity to nabumetone (Nabumetone) or related compounds.

2. Conditions that affected the absorption, metabolism, or passage of drugs out of the body (eg, sprue, celiac disease, Crohn's disease, colitis, liver, kidney, or thyroid conditions).

3. Recent history (within 1 year) of mental illness, drug addiction, drug abuse, or alcoholism.

4. A hematocrit value of ≤ 33.0% for females and ≤ 37.0% for males.

5. Donation of > 500 mL of blood in the past 8 weeks prior to study drug dosing or difficulty in donating blood.

6. Receipt of an investigational drug within the 4 weeks prior to study drug dosing.

7. Currently taking any systemic prescription medications, excluding hormone contraceptives, within the 7 days prior to study dosing or over-the-counter medication within 3 days of study dosing. This prohibition did not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications, as judged by the attending physician.

Any nonprescription medication consumption reported was to be reviewed by the investigator prior to dosing. At the discretion of the investigator, these volunteers could be enrolled if the medication was not anticipated to alter study integrity.

8. Regular smoking of more than 5 cigarettes weekly or the regular daily use of nicotinecontaining products beginning 3 months before study drug administration through the final evaluation.

9. Female subjects who were lactating or had a positive pregnancy test at Screening and prior to each of the treatment periods.

10. Alcohol, grapefruit beverages or foods, caffeine, or xanthine beverages or foods beginning 48 hours before each study drug administration through the last pharmacokinetic (PK) sample of each treatment period. Such restricted items included coffee, tea, iced tea, Coke®, Pepsi®, Mountain Dew®, chocolate, brownies, etc.

11. Regular use of any drugs known to induce or inhibit hepatic drug metabolism (examples include barbiturates, carbamazepine, rifampin, phenylhydantoins, phenothiazines, cimetidine, omeprazole, macrolides, imidazoles, fluoroquinolones) within 30 days prior to study drug administration.

12. Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C antibody at Screening.

No subject was allowed to enroll in this study more than once.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Actavis Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Evin H. Sides III, M.D.

Role: PRINCIPAL_INVESTIGATOR

AAIPharma Inc., AAI Clinic

Locations

AAIPharma Inc., AAI Clinic

Morrisville, North Carolina, United States

Countries

United States

Other Identifiers

AAI-US-492

Identifier Type: -

Identifier Source: org_study_id